Chengdu Easton Biopharmaceuticals Co., Ltd. (SHA:688513)

China · Delayed Price · Currency is CNY

45.56

-2.54 (-5.28%)

Aug 21, 2026, 3:00 PM CST

-26.52% (1Y)

Market Cap	7.94B -25.9%
Revenue (ttm)	1.34B +0.1%
Net Income	277.24M +21.4%
EPS	1.60 +23.1%
Shares Out	174.35M
PE Ratio	28.47
Forward PE	26.80
Dividend	0.49 (1.09%)
Ex-Dividend Date	Jun 2, 2026

Volume	2,857,949
Open	47.62
Previous Close	48.10
Day's Range	44.91 - 47.65
52-Week Range	40.25 - 80.48
Beta	0.04
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 21, 2026

About SHA:688513

Chengdu Easton Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, and commercialization of pharmaceutical products in China and internationally. The company offers active pharmaceutical ingredients; finished dosage forms, including capsules, tablets, and injections; pharmaceutical intermediates; biological drugs; and generic drugs. Its products are used in oncology, cardiovascular, neurology and psychiatry, anesthetic and analgesics, urinary, anti-inflammatory, anti-diabetes, anthe... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2009

Employees 1,480

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688513

Full Company Profile

Financial Performance

In 2025, SHA:688513's revenue was 1.33 billion, a decrease of -1.36% compared to the previous year's 1.35 billion. Earnings were 284.06 million, an increase of 19.24%.

Financial Statements